-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MkD8AkFeag/Upuw6VQzFMtBlqNfVpqDl1SROwg41bHMpQgQbbIinhKje1CeTJDhk usEJfsGAXrLjxsDDfZDd0Q== 0001144204-05-007629.txt : 20050315 0001144204-05-007629.hdr.sgml : 20050315 20050315151401 ACCESSION NUMBER: 0001144204-05-007629 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050224 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050315 DATE AS OF CHANGE: 20050315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAZON BIOTECH INC CENTRAL INDEX KEY: 0001088781 STANDARD INDUSTRIAL CLASSIFICATION: [9995] IRS NUMBER: 870416131 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26753 FILM NUMBER: 05681473 BUSINESS ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 BUSINESS PHONE: (212) 695-3003 MAIL ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 FORMER COMPANY: FORMER CONFORMED NAME: ASYST CORP DATE OF NAME CHANGE: 19990615 8-K 1 v14369_8k.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) FEBRUARY 24, 2005 ------------------- AMAZON BIOTECH, INC. ------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) UTAH 0-26753 87-0416131 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 43 WEST 33RD STREET, SUITE 405, NEW YORK, NEW YORK 10001 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (212) 695-3003 - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(C) under the Exchange Act (17 CFR 240.13e-4(c)) 1 SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. Not applicable. ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT. Not applicable. ITEM 1.03 BANKRUPTCY OR RECEIVERSHIP. Not applicable. SECTION 2 - FINANCIAL INFORMATION ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS. Not applicable. ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. Not applicable. ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. Not applicable. ITEM 2.04 TRIGGERING EVENTS THAT ACCELERATE OR INCREASE A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT. Not applicable. ITEM 2.05 COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES. Not applicable. ITEM 2.06 MATERIAL IMPAIRMENTS. Not applicable. SECTION 3 - SECURITIES AND TRADING MARKETS ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD: TRANSFER OF LISTING. Not applicable. ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. MARCH PRIVATE PLACEMENT. On March 7, 2005, Amazon Biotech closed a private placement for the sale of 300,000 units at a price of $0.50 per unit, each unit consisting of one share of Amazon Biotech common stock and one warrant to purchase one share of common stock at an exercise price of $1.13 per share. Amazon Biotech received $150,000 in gross proceeds from the sale of the units and may receive additional gross proceeds of approximately $339,000 from the exercise of the unit warrants. It is possible that none of the unit warrants will ever be exercised. 2 In connection with the offer and sale of the units, Amazon Biotech relied on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended. Amazon Biotech agreed to file a registration statement covering the secondary offering and resale of the shares and the shares underlying the unit warrants issued as part of the units within eighty days of the closing of the sale of the units. In connection with the offer and sale of the units, Amazon Biotech engaged Parker Financial Corp., an NASD licensed broker-dealer, as a finder. Amazon Biotech paid to Parker Financial Corp. a finder's fee of $25,000 and a warrant to purchase 125,000 shares of our common stock at an exercise price of $1.13 per share. FEBRUARY PRIVATE PLACEMENT. On February 24, 2005, Amazon Biotech closed the final traunche of a private placement for the sale of 400,000 units at a price of $0.50 per unit, each unit consisting of one share of Amazon Biotech common stock, one warrant to purchase one share of common stock at an exercise price of $0.58 per share, and one warrant to purchase one share of common stock at an exercise price of $0.72 per share. The first traunche of this private placement closed on November 2, 2004, and the second traunche closed on December 15, 2004. Amazon Biotech received $200,000 in gross proceeds from the sale of the units and may receive additional gross proceeds of approximately $520,000 from the exercise of the unit warrants. It is possible that none of the unit warrants will ever be exercised. In connection with the offer and sale of the units, Amazon Biotech relied on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended. Amazon Biotech agreed to file a registration statement covering the secondary offering and resale of the shares and the shares underlying the unit warrants issued as part of the units within eighty days of the final closing of the sale of the units. PREVIOUS PRIVATE PLACEMENTS. As previously reported, from February 2004 through July 2004, Amazon Biotech raised $268,500 in gross proceeds from various private placements of f shares of common stock and units consisting of shares of common stock and warrants to purchase common stock. In total, Amazon Biotech issued an aggregate of 1,120,000 shares of common stock and warrants to purchase an aggregate of 270,000 shares of common stock at and exercise price of $6.00 per share. In connection with the offer and sale of these securities, Amazon Biotech relied on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended. ITEM 3.03 MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS. Not applicable. SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT. Not applicable. ITEM 4.02 NON-RELIANCE ON PREVIOUSLY ISSUED FINANCIAL STATEMENTS OR A RELATED AUDIT REPORT OR COMPLETED INTERIM REVIEW. Not applicable. SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT. Not applicable. 3 ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. Not applicable. ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS: CHANGE IN FISCAL YEAR. Not applicable. ITEM 5.04 TEMPORARY SUSPENSION OF TRADING UNDER REGISTRANT'S EMPLOYEE BENEFIT PLANS. Not applicable. ITEM 5.05 AMENDMENTS TO THE REGISTRANT'S CODE OF ETHICS, OR WAIVER OF A PROVISION OF THE CODE OF ETHICS. Not applicable. SECTION 6 - [RESERVED] Not applicable. SECTION 7 - REGULATION FD ITEM 7.01 REGULATION FD DISCLOSURE. On March 14, 2005, we issued a press release announcing the private placements. A copy of the press release containing such announcement is furnished herewith as Exhibit 99.1 and incorporated herein by reference. SECTION 8 - OTHER EVENTS ITEM 8.01 OTHER EVENTS. Not applicable. SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (a) Financial Statements of Businesses Acquired. Not applicable. (b) Pro Forma Financial Information. Not applicable. (c) Exhibits. 99.1 Press Release 4 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMAZON BIOTECH, INC. (Registrant) Date: March 15, 2005 By: /s/ Mechael Kanovsky, Ph.D. --------------------------- Mechael Kanovsky, Ph.D., President 5 EX-99.1 2 v14369_ex99-1.txt AMAZON BIOTECH ANNOUNCES IT HAS RAISED $600,000 TO ADVANCE PRODUCT DEVELOPMENT AND SEEKS UP TO $6 MILLION IN ADDITIONAL CAPITAL New York, New York, March 14, 2005 -- Amazon Biotech, Inc. (OTCBB: AMZB), a developer and producer of AMZ 0026, a potential immunomodulator drug developed for use in the treatment of the HIV virus, announced today that it has raised a total of $618,500 in gross proceeds in equity capital private placements since February, 2004. Mechael Kanovsky, Ph.D., President of Amazon Biotech, said: "We are gratified by the response to our offerings. The proceeds are being used to fund our clinical studies and our immediate general working capital needs. We are continuing to seek up to an additional $6 million in equity capital through a private placement or joint venture to fund our research and development, clinical studies, and future working capital needs." Further information regarding the terms of the private placements can be found in Amazon Biotech's current report on Form 8-K filed today with the Securities and Exchange Commission. About Amazon Biotech Amazon Biotech, Inc. is a Biotech /Pharmaceutical company currently producing AMZ 0026, an Immune Modulator Drugs. The company intends to initiate Phase I/II clinical studies of AMZ 0026 in the near future, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials. During 2005, Amazon Biotech plans to conduct a double blind study on its hair growth product. The company also plans to market the hair growth product through a Fortune 1000 company. Additional information on Amazon Biotech may be found at http://www.amazonbiotech.com. FORWARD LOOKING STATEMENTS: "Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Contact: Investor Relations Richard E. Cooper / Jennifer K. Zimmons, Ph.D. Strategic Growth International, Inc. jzimmons@sgi-ir.com 212-838-1444 - ------------------------ Source: Amazon Biotech, Inc. -----END PRIVACY-ENHANCED MESSAGE-----